Neuropace (NPCE) Stock: Buy, Sell, or Hold?
NPCE - Neuropace, Inc. Common Stock
$12.85
-0.30 (-2.28%)
▼
5d:
-8.61%
30d:
-15.4%
90d:
-25.85%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When NPCE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NPCE shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NPCE shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: NPCE is currently trading at $12.85, which is considered oversold relative to its 30-day fair value range of $13.77 to $14.74.
Technical Outlook: Technically, NPCE is in a downtrend. The price is currently testing key support at $12.84. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (26th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $20.00 (+52.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NPCE is in a downtrend. The price is currently testing key support at $12.84. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (26th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $20.00 (+52.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$13.77 -
$14.74
Company Quality Score
42/100
(HOLD)
Options IV Signal
26th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
86.2%
Protect Your Profits
Holding NPCE? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 26th percentile)
- NEUTRAL: Mixed technical signals (41/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 52.1% below Wall St target ($20.00)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$13.77 -
$14.74
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.28
(9.9%)
Support & Resistance Levels
Support Level
$12.84
Resistance Level
$14.93
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-60.46
Wall Street Target
$20.00
(+52.1%)
Revenue Growth (YoY)
17.1%
Profit Margin
-17.9%
Share & Embed Analysis
Last updated: October 02, 2026 1:51 PM ET
Data refreshes hourly during market hours. Next update: 2:51 PM
Data refreshes hourly during market hours. Next update: 2:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NPCE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$61 | 62 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 47 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 64 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 51 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 38 SELL |
Advanced NPCE Option Strategies
Professional options setups generated by AI based on today's NPCE price and gamma walls.
